All In Biotech

Drug Trial Radar · NCT06979076

A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL

A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Last checked: Nov 19, 2026Latest source record: Sep 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

Jul 2026

Primary completion

Sep 2028

Study completion Dec 2028

Sponsor

Lead sponsor
MingSight Pharmaceuticals, IncIndustry
Sponsor type
Industry
First posted
May 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients with Refractory or Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Conditions

  • CLL (Chronic Lymphocytic Leukemia)
  • SLL (Small Lymphocytic Lymphoma)

Interventions

  • MS-553, DS1Drug

    Oral, Dose Schedule 1

  • MS-553, DS2Drug

    Oral, Dose Schedule 2

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The occurrence of AEs and SAEs, with abnormal laboratory tests results, abnormal physical examination findings, abnormal vital signs, and abnormal ECG readingsTime frame: Through study completion, an average of 2 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.